Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C) ((IBS-C))
Irritable Bowel Syndrome With Constipation
About this trial
This is an interventional treatment trial for Irritable Bowel Syndrome With Constipation
Eligibility Criteria
INCLUSION CRITERIA
A patient will be eligible for study participation if he or she meets all of the following criteria:
- Male or female child aged 6 to < 18;
- Meets ROME IV criteria for child/adolescent IBS-C
- Patient's parent/guardian/LAR is able to voluntarily provide written, signed, and dated consent and patient is able to voluntarily provide assent as per IRB guidance;
- Patient and patient's parent/guardian/LAR demonstrates an understanding, ability, and willingness to fully comply with study procedures
EXCLUSION CRITERIA
A patient will be excluded from the study if he or she meets any of the following criteria:
- The patient has a mental age <4 years in the investigator's opinion;
- The patient has previously been diagnosed with anorectal malformations, neurological deficits, or anatomical anomalies that would constitute a predisposition to constipation;
- The patient is pregnant or lactating;
- The patient's mobility or normal exercise tolerance is compromised in the investigator's opinion;
- The patient has been screened for or participated in another Synergy study in the past;
- The patient has a sibling that is currently participating or has participated in another Synergy study.
Sites / Locations
- Synergy Research SiteRecruiting
- Synergy Research SiteRecruiting
- Synergy Research SiteRecruiting
- Synergy Research SiteRecruiting
- Synergy Research SiteRecruiting
- Synergy Research SiteRecruiting
- Synergy Research SiteRecruiting
- Synergy Research SiteRecruiting
- Synergy Research SiteRecruiting
- Synergy Research SiteRecruiting
- Synergy Research SiteRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Experimental
Experimental
Experimental
Experimental
Placebo Comparator
0.5 mg plecanatide
1.0 mg plecanatide
2.0 mg plecanatide
3.0 mg plecanatide
Matching placebo
Plecanatide 0.5 mg Taken orally once daily for 4 weeks Group A: 6 to 11 years old
Plecanatide 1.0 mg Taken orally daily for 4 weeks Group A: 6 to 11 years old Group B: 12 to < 18 years old
Plecanatide 2.0 mg Taken orally daily for 4 weeks Group B: 12 to < 18 years old
Plecanatide 3.0 mg Taken orally daily for 4 weeks Group B: 12 to < 18 years old
Matching placebo Taken orally daily for 4 weeks Group A: 6 to 11 years old Group B: 12 to < 18 years old